8 Questions on Managing Lung Cancer

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Experts weigh in on the practical applications of PSMA PET imaging

Ashling Wahner

Exploring Burnout Causes and Management in Oncologic Practice

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Eric P. Winer, MD

June 2nd 2025

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Chris Ryan

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Related Content

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Experts weigh in on the practical applications of PSMA PET imaging

Ashling Wahner

Exploring Burnout Causes and Management in Oncologic Practice

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

Eric P. Winer, MD

June 2nd 2025

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Chris Ryan